// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Pathophysiology of perianal fistulising disease

B. Siegmund - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in inflammatory bowel disease patients with primary sclerosing cholangitis; a six year experience

K. Hartery - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

The virtual electronic chromoendoscopy score in ulcerative colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: a study across academic and community practice

P. Trivedi - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

The role of intestinal transplant in patients with complicated inflammatory bowel disease: the Cambridge experience

S.P. Yeap - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Tight NADPH oxidase regulation is a prerequisite for gut health

G. Aviello - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Sodium sulfate

Establishing a porcine model to translate anorectal stem cell organoid models to elucidate the aetiology of perianal Crohn's fistulae

S. Adegbola - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Collagenase

Transcriptomic profiling of intestinal macrophages isolated from patients reveals a profound gene expression reprogramming underlying IBD pathogenesis

S. Dharmasiri - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Complete metabonomic and microbiota profiling identifies biomarkers for anti-TNF therapy response

N.S. Ding - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparing the immunological signatures of inflammatory diseases

E. McDonald - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The pharmacological profile of TOP1288, a narrow spectrum kinase inhibitor in clinical development as an anti-inflammatory treatment for ulcerative colitis

M. Foster - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab

B. Verstockt - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Infliximab

Human peripheral blood monocytes and intestinal macrophage populations activate transforming growth factor beta via expression of the integrin alpha v beta 8

E. Shuttleworth - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

MDR1-deficiency unmasks mitochondrial dysfunction as a pathogenic mechanism in IBD

G.-T. Ho - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

SOD-2

Ulcerative colitis is characterised by an exaggerated onset of acute inflammation with delayed resolution

D. Marks - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

5-Aminosalicylates promote inflammation resolution in ulcerative colitis through generation of anti-inflammatory hydroxy fatty acids

R. Wysoczanski - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for α4β7 in myeloid cell recruitment to the inflamed intestine

H. Gordon - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

Mitochondrial DNA is a damage-associated molecular pattern released during active IBD promoting TLR9-mediated inflammation

R. Boyapati - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Gut microbiota characterisation in South Asian IBD patients resident in the UK

M.N. Quraishi - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Comparison of Calprotectin levels in stool and rectal mucus in subjects with suspected or confirmed inflammatory bowel disease

J. McLaughlin - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Mucosal inflammation promotes activation of circulating Vδ2+ T-cells in Crohn's disease

N. McCarthy - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved